Myriad Genetics (MYGN)

Myriad Genetics Stock Analysis & Ratings

MYGN Stock Chart & Stats

Day’s Range$21.89 - $22.585
52-Week Range$18.98 - $36.95
Previous Close$22.37
Average Volume (3M)545.40K
Market Cap$1.77B
P/E Ratio-199.9
Next EarningsAug 02, 2022
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.11



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $18.98 and its highest was $36.95 in the past 12 months.
    What is Myriad Genetics’s market cap?
    Myriad Genetics’s market cap is $1.77B.
      What is Myriad Genetics’s price target?
      The average price target for Myriad Genetics is $28.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $42.00 ,the lowest forecast is $20.00. The average price target represents 28.12% Increase from the current price of $22.01.
        What do analysts say about Myriad Genetics?
        Myriad Genetics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 5 Wall Streets Analysts.
          When is Myriad Genetics’s upcoming earnings report date?
          Myriad Genetics’s upcoming earnings report date is Aug 02, 2022 which is in 76 days.
            How were Myriad Genetics’s earnings last quarter?
            Myriad Genetics released its earnings results on May 05, 2022. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.053.
              Is Myriad Genetics overvalued?
              According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
                Does Myriad Genetics pay dividends?
                Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. Myriad Genetics’s last Notavailable dividend payment was on Jun 30, 2009. Myriad Genetics’s upcoming ex-dividend date is Jun 15, 2009
                  What is Myriad Genetics’s EPS estimate?
                  Myriad Genetics’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Myriad Genetics have?
                  Myriad Genetics has 80,340,000 shares outstanding.
                    What happened to Myriad Genetics’s price movement after its last earnings report?
                    Myriad Genetics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went down -1.053%.
                      Which hedge fund is a major shareholder of Myriad Genetics?
                      Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 44M.


                        Myriad Genetics Stock Analysis

                        Smart Score
                        Price Target
                        ▲(28.12% Upside)
                        The Myriad Genetics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Myriad Genetics

                        Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

                        Similar Stocks
                        Price & Change
                        Fulgent Genetics
                        Aspira Women's Health

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis